Surmodics Appoints Lisa Wipperman Heine to Its Board of Directors
April 17 2017 - 8:00AM
Business Wire
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical
device and in vitro diagnostic technologies to the healthcare
industry, today announced the addition of Lisa Wipperman Heine to
the Company’s Board of Directors, effective on April 12, 2017.
Ms. Wipperman Heine has spent over 25 years in leadership
positions in the medical device industry. She is currently the
Chief Operating Officer at Mitralign, an innovator in transcatheter
tricuspid and mitral valve therapies. Prior to joining Mitralign,
Wipperman Heine was the Founder and Principal at deArca Strategic
Solutions, LLC, a consulting firm focused on helping medtech
companies assess, develop and execute strategies related to market
opportunities and technology adoption. She has also served in
multiple leadership roles at Covidien, Inc., including Global Vice
President of Medical Affairs for Vascular Therapies. During her
tenure at Covidien, Wipperman Heine helped drive the strategy in
support of a $1.7B business and was also responsible for leading
the strategy and operations of Clinical Affairs, Healthcare
Economics, Policy and Reimbursement and Medical Education
functions. Wipperman Heine received her M.S. degree from the
University of Manitoba and her B.A. degree from St. Olaf
College.
“We are pleased that Lisa Wipperman Heine will be joining our
board,” said Gary Maharaj, President and Chief Executive Officer.
“Lisa brings a broad range of experience in strategic roles and in
developing devices for vascular repair, and we look forward to her
contributions as we continue to work toward achieving our goal of
improving the lives of patients. She joins Surmodics at an exciting
time as we are preparing to deliver on many milestones including
advancing our pipeline products in clinical trials.”
“I am honored to join a company that is focused on creating life
changing products for patients,” said Lisa Wipperman Heine.
“Surmodics continues to differentiate itself as a leader in the
medical device sector with an evolving business model, and I look
forward to providing additional insight as the company continues to
grow and build out its business.”
About Surmodics, Inc.
Surmodics is the global leader in surface modification
technologies for intravascular medical devices and a leading
provider of chemical components for in vitro diagnostic (IVD) tests
and microarrays. Following two recent acquisitions of Creagh
Medical and NorMedix, the Company is executing a key growth
strategy for its medical device business by expanding to offer
total intravascular product solutions to its medical device
customers. The combination of proprietary surface technologies,
along with enhanced device design, development and manufacturing
capabilities, enables Surmodics to significantly increase the value
it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements.
With this focus on offering total solutions, Surmodics’ mission
remains to improve the detection and treatment of disease.
Surmodics is headquartered in Eden Prairie, Minnesota. For more
information about the company, visit www.surmodics.com. The content
of Surmodics’ website is not part of this press release or part of
any filings that the company makes with the SEC.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170417005246/en/
Surmodics, Inc.Andy LaFrence, 952-500-7000ir@surmodics.com
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Sep 2023 to Sep 2024